Argenx Se (ARGX) Cash & Current Investments (2015 - 2026)
Argenx Se's (ARGX) quarterly Cash & Current Investments came in at $5.2 billion in Q2 2026, down 99.55% YoY from $1156.3 billion in Q2 2025, and up 16.76% on a QoQ basis from $4.4 billion in Q4 2025.
Argenx Se (ARGX) Cash & Current Investments (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Cash & Current Investments data on file, last reported at $5.2 billion in Q2 2026.
- Quarterly Cash & Current Investments fell 99.55% year-over-year to $5.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.2 billion (down 99.55% YoY) and the FY2025 annual result came in at $5.9 billion, up 960.14% from the prior year.
- Cash & Current Investments advanced to $5.2 billion in Q2 2026, from $4.4 billion in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $1156.3 billion in Q2 2025 to a low of -$1107.0 billion in Q2 2024.
- A 5-year average of $8.0 billion and a median of $3.2 billion in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2024 — Cash & Current Investments plunged 55532.62% — and 2025, when it jumped 204.46%.
- Tracing ARGX's Cash & Current Investments over 5 years: stood at $2.2 billion in 2022, then surged by 45.03% to $3.2 billion in 2023, then increased by 6.26% to $3.4 billion in 2024, then jumped by 31.4% to $4.4 billion in 2025, then increased by 16.76% to $5.2 billion in 2026.
- The last three Cash & Current Investments figures came in at $5.2 billion (Q2 2026), $4.4 billion (Q4 2025), and $1156.3 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.18 Bn |
| Dec 31, 2025 | 4.44 Bn |
| Jun 30, 2025 | 1,156.35 Bn |
| Dec 31, 2024 | 3.38 Bn |
| Jun 30, 2024 | -1,106.97 Bn |
| Dec 31, 2023 | 3.18 Bn |
| Jun 30, 2023 | 2.00 Bn |
| Dec 31, 2022 | 2.19 Bn |
| Jun 30, 2022 | 2.60 Bn |
| Dec 31, 2021 | 2.34 Bn |
| Jun 30, 2021 | 2.73 Bn |
| Dec 31, 2020 | 1.94 Bn |
| Jun 30, 2020 | 2.13 Bn |
| Dec 31, 2019 | 1.48 Bn |
| Jun 30, 2019 | 1.06 Bn |
| Dec 31, 2018 | 644.40 Mn |
| Jun 30, 2018 | 404.40 Mn |
| Dec 31, 2017 | 423.61 Mn |
| Jun 30, 2017 | 190.69 Mn |
| Dec 31, 2016 | 104.44 Mn |